Figure 6. SC rFVIIIFc and the rFVIIIFc demonstrated equivalent in vivo efficacy in a HemA mouse bleeding model.

Tail-bleeding of HemA mice was induced via transection of one of the lateral veins at 48 hr post i.v. dosing of SC rFVIIIFc or rFVIIIFc (0.46, 1.38 and 4.6 µg/kg). Mice were monitored for survival and re-bleeding for 24 hr post injury. (A) Schematic experimental design of TVT model. (B) 24 hr post TVT survival curves (C) 24 hr post TVT re-bleeding curves from experimental animals. (D) The linear regression curve of the percentage of protection (survival rate) versus the log (base 10) of the dose was plotted. The ED₅₀ was extrapolated from the curves.